. Author manuscript; available in PMC: 2017 Sep 26.

Published in final edited form as: Am J Obstet Gynecol. 2015 Jul 26;214(1):22–30. doi: 10.1016/j.ajog.2015.07.022

Table 3.

Other anti-angiogenesis agents in cervical cancer treatment

Trial	Lead Author	Pathology	Arms	RR (%)	OS (weeks)	PFS (weeks)	Conclusion

NCIC CTG IND.184	Mackay³⁴	SCC, AS, or adenocarcinoma	Sunitinib 50mg daily for 4 weeks	0	NR	24.6	Higher rate of fistula formation (26.3%) than expected. Insufficient activity as single agent.

	Monk^35,36	SCC, AS, or adenocarcinoma	Pazopanib 800mg Lapatinib 1,500mg	9	50.7	18.1	Pazopanib improved PFS and OS.
	Monk^35,36	SCC, AS, or adenocarcinoma	Pazopanib 800mg Lapatinib 1,500mg	5	39.1	17.1	Pazopanib improved PFS and OS.

CRUK/10/001	Symonds³⁷	SCC, AS, or adenocarcinoma	Cediranib 20mg po daily + Carboplatin AUC5 + Paclitaxel 175mg/m² every 21 days Placebo daily + Carboplatin AUC5 + Paclitaxel 175mg/m² every 21 days	66	59	35	Addition of cediranib to carboplatin and paclitaxel results in prolonged PFS with no change in OS.
CRUK/10/001	Symonds³⁷	SCC, AS, or adenocarcinoma		42	63	30

RR response rate, OS mean overall survival, PFS mean progression free survival, NR no reported